Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Adagene Inc (ADAG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: ADAG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.75
1 Year Target Price $5.75
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.84% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 90.45M USD | Price to earnings Ratio - | 1Y Target Price 5.75 |
Price to earnings Ratio - | 1Y Target Price 5.75 | ||
Volume (30-day avg) 3 | Beta 0.74 | 52 Weeks Range 1.32 - 3.58 | Updated Date 06/30/2025 |
52 Weeks Range 1.32 - 3.58 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -17082.39% |
Management Effectiveness
Return on Assets (TTM) -21.92% | Return on Equity (TTM) -55.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23749382 | Price to Sales(TTM) 876.42 |
Enterprise Value 23749382 | Price to Sales(TTM) 876.42 | ||
Enterprise Value to Revenue 230.12 | Enterprise Value to EBITDA 1.12 | Shares Outstanding 47109600 | Shares Floating 12798488 |
Shares Outstanding 47109600 | Shares Floating 12798488 | ||
Percent Insiders 4.7 | Percent Institutions 34.89 |
Analyst Ratings
Rating 2 | Target Price 5.75 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Adagene Inc
Company Overview
History and Background
Adagene Inc. is a clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Founded in 2011, Adagene focuses on developing cutting-edge antibody therapies based on its DPL technology platform.
Core Business Areas
- Antibody Discovery and Development: Adagene utilizes its Dynamic Precision Library (DPL) technology to discover and develop fully human therapeutic antibodies.
- Oncology Immunotherapy: The company focuses on developing novel immunotherapies for cancer treatment.
- Clinical Trials: Adagene conducts clinical trials to evaluate the safety and efficacy of its antibody candidates.
Leadership and Structure
The company has a leadership team with experience in biotechnology, drug development, and clinical research. The organizational structure includes research, development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- ADG106 (CD137 agonist): ADG106 is a fully human, agonistic anti-CD137 IgG4 antibody designed for enhanced safety and efficacy. It's in clinical development for advanced solid tumors. No specific market share data is available at this stage. Competitors include other CD137 agonists in development by various companies.
- ADG126 (CTLA-4 conditional blocker): ADG126 is a novel masked antibody designed to block CTLA-4 in the tumor microenvironment, potentially reducing systemic toxicity. It's in clinical development. No specific market share data is available at this stage. Competitors include other CTLA-4 inhibitors like ipilimumab (Yervoy) from Bristol-Myers Squibb.
- ADG116 (Anti-CTLA-4):: An anti-CTLA-4 masked antibody designed to be tumor-microenvironment activated, reducing systemic toxicity. Currently in clinical trials. Competitors are Yervoy and other CTLA-4 inhibitors.
Market Dynamics
Industry Overview
The oncology immunotherapy market is experiencing significant growth, driven by advances in understanding the immune system and the development of novel antibody-based therapies. Competition is intense with many companies developing new cancer treatments.
Positioning
Adagene is positioned as an innovative company leveraging its DPL technology platform to discover and develop differentiated antibody therapies with potentially improved safety and efficacy profiles.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Adagene is positioned to capture a portion of this TAM by developing innovative immunotherapies. The exact percentage is unknown and depends on clinical trial success and market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary DPL technology platform
- Focus on developing differentiated antibody therapies
- Experienced management team
- Pipeline of novel immunotherapies
Weaknesses
- Clinical-stage company with no products currently on the market
- Dependence on successful clinical trial outcomes
- Relatively small market capitalization compared to established pharmaceutical companies
- Potential for competition from larger pharmaceutical companies
Opportunities
- Potential to partner with larger pharmaceutical companies
- Expansion of pipeline through further development of DPL technology
- Positive clinical trial results leading to regulatory approval
- Addressing unmet medical needs in oncology
Threats
- Failure of clinical trials
- Competition from other immunotherapies
- Changes in regulatory environment
- Difficulty in securing financing
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- AZN
Competitive Landscape
Adagene competes with both established pharmaceutical companies and other biotechnology companies in the oncology immunotherapy space. Its competitive advantage lies in its DPL technology and differentiated antibody therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by investment in research and development, advancement of pipeline candidates through clinical trials, and securing partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its antibody therapies. Analyst estimates vary.
Recent Initiatives: Recent initiatives include progressing clinical trials for ADG106 and ADG126, and exploring new applications of its DPL technology.
Summary
Adagene is a clinical-stage biopharmaceutical company with a promising technology platform for developing novel antibody-based cancer immunotherapies. The company faces the typical risks associated with drug development, but its differentiated approach and strong pipeline provide opportunities for growth. Positive clinical trial results and strategic partnerships will be key to its success. The low market share and high competition highlight the need for Adagene to innovate and execute its strategic plan effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adagene Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-09 | Co- Founder, Chairman, CEO and President of R&D Dr. Peter P. Luo Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 138 | Website https://www.adagene.com |
Full time employees 138 | Website https://www.adagene.com | ||
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.